Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the effect of ixazomib maintenance therapy on progression-free survival (PFS), defined as the time from randomization to progressive disease (PD) or death from any cause, compared with placebo, in patients with NDMM who have had a major response - defined as complete response (CR), very good partial response (VGPR), or partial response (PR) - to initial therapy and who have not undergone SCT
Critère d'inclusion
- Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation